Comparison of clinical variables at presentation between WT and mutant TET2*
| Variable† . | TET2 mutant . | TET2 WT . | P . |
|---|---|---|---|
| Age (n = 60) | |||
| ≥ 60 y | 17 | 31 | .21 |
| < 60 y | 2 | 10 | |
| Sex‡ (n = 61) | |||
| Male | 18 | 24 | .003 |
| Female | 1 | 18 | |
| Hemoglobin§ (n = 61) | |||
| ≥ 10 g/dL | 7 | 22 | .38 |
| < 10 g/dL | 11 | 21 | |
| WBC count (n = 61) | |||
| ≥ 10 × 109/L | 13 | 12 | .01 |
| < 10 × 109/L | 8 | 28 | |
| Platelet count (n = 62) | |||
| ≥ 450 × 109/L | 1 | 3 | .65 |
| 150-450 × 109/L | 5 | 7 | |
| < 150 × 109/L | 13 | 33 | |
| Absolute monocyte count (n = 62) | |||
| ≥ 1 × 109/L | 12 | 15 | .03 |
| < 1 × 109/L | 7 | 28 | |
| Number of cytopenias (n = 61) | |||
| 0 | 4 | 6 | .74 |
| 1 | 5 | 16 | |
| 2 | 7 | 14 | |
| 3 | 2 | 7 | |
| Palpable splenomegaly (n = 62) | |||
| Yes | 9 | 19 | .82 |
| No | 10 | 24 | |
| Metaphase cytogenetics§ (n = 60) | |||
| Normal | 11 | 12 | .07 |
| Abnormal | 8 | 24 | |
| Bone marrow blasts§ (n = 61) | |||
| ≥ 5% | 6 | 21 | .17 |
| < 5% | 13 | 21 | |
| Bone marrow cellularity (n = 56) | |||
| Hypercellular | 16 | 28 | .44 |
| Normocellular | 3 | 6 | |
| Hypocellular | 0 | 3 | |
| No. dysplastic BM cell lines (n = 59) | |||
| 0 | 5 | 18 | .09 |
| 1 | 7 | 4 | |
| 2 | 4 | 10 | |
| 3 | 3 | 8 | |
| Bone marrow megakaryocytes (n = 57) | |||
| Dysplastic | 10 | 22 | .94 |
| Normal | 8 | 17 | |
| Progression to AML (n = 62) | |||
| Yes | 14 | 21 | .06 |
| No | 5 | 22 |
| Variable† . | TET2 mutant . | TET2 WT . | P . |
|---|---|---|---|
| Age (n = 60) | |||
| ≥ 60 y | 17 | 31 | .21 |
| < 60 y | 2 | 10 | |
| Sex‡ (n = 61) | |||
| Male | 18 | 24 | .003 |
| Female | 1 | 18 | |
| Hemoglobin§ (n = 61) | |||
| ≥ 10 g/dL | 7 | 22 | .38 |
| < 10 g/dL | 11 | 21 | |
| WBC count (n = 61) | |||
| ≥ 10 × 109/L | 13 | 12 | .01 |
| < 10 × 109/L | 8 | 28 | |
| Platelet count (n = 62) | |||
| ≥ 450 × 109/L | 1 | 3 | .65 |
| 150-450 × 109/L | 5 | 7 | |
| < 150 × 109/L | 13 | 33 | |
| Absolute monocyte count (n = 62) | |||
| ≥ 1 × 109/L | 12 | 15 | .03 |
| < 1 × 109/L | 7 | 28 | |
| Number of cytopenias (n = 61) | |||
| 0 | 4 | 6 | .74 |
| 1 | 5 | 16 | |
| 2 | 7 | 14 | |
| 3 | 2 | 7 | |
| Palpable splenomegaly (n = 62) | |||
| Yes | 9 | 19 | .82 |
| No | 10 | 24 | |
| Metaphase cytogenetics§ (n = 60) | |||
| Normal | 11 | 12 | .07 |
| Abnormal | 8 | 24 | |
| Bone marrow blasts§ (n = 61) | |||
| ≥ 5% | 6 | 21 | .17 |
| < 5% | 13 | 21 | |
| Bone marrow cellularity (n = 56) | |||
| Hypercellular | 16 | 28 | .44 |
| Normocellular | 3 | 6 | |
| Hypocellular | 0 | 3 | |
| No. dysplastic BM cell lines (n = 59) | |||
| 0 | 5 | 18 | .09 |
| 1 | 7 | 4 | |
| 2 | 4 | 10 | |
| 3 | 3 | 8 | |
| Bone marrow megakaryocytes (n = 57) | |||
| Dysplastic | 10 | 22 | .94 |
| Normal | 8 | 17 | |
| Progression to AML (n = 62) | |||
| Yes | 14 | 21 | .06 |
| No | 5 | 22 |